The expression of p16 (INK4a) and Ki-67 in relation to high-risk human papilloma viral load and residual disease after conization with positive margins

International Journal of Gynecological Cancer

Volumn 17, Issue 4, 2007, Pages 858-867

  Song, S H ^a   Park, H M ^b   Eom, D W ^b   Lee, J K ^a   Lee, N W ^a   Kim, A R ^a   Hur, J Y ^a   Lee, K W ^a   Park, Y K ^a   Saw, H S ^a,c  

^a Korea University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

Author keywords

Conization; HPV; Ki 67; p16 (INK4a); Viral load

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN ANTIBODY; PROTEIN P16INK4A; VIRUS DNA;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION RISK; MINIMAL RESIDUAL DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SAMPLE; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VIRUS LOAD; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PAPILLOMAVIRUS INFECTIONS; RISK; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 34447300470     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00891.x     Document Type: Article

References (42)

1. Andersen ES, Nielsen K, Pedersen B. The reliability of preconization diagnostic evaluation in patients with cervical intraepithelial neoplasia and microinvasive carcinoma. Gynecol Oncol 1995 59: 143 7.
2. Chao A, Lin CT, Hsueh S et al. Usefulness of human papillomavirus testing in the follow-up of patients with high-grade cervical intraepithelial neoplasia after conization. Am J Obstet Gynecol 2004 190: 1046 51.
3. Zielinski GD, Bais AG, Helmerhorst TJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004 59: 543 53.
4. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998 92: 737 44.
5. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999 91: 252 8.
6. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet 2000 68: 25 33.
7. Alonso I, Torne A, Puig-Tintore LM et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006 103: 631 6.
8. Song SH, Lee JK, Oh MJ et al. Persistent HPV infection after conization in patients with negative margins. Gynecol Oncol 2006 101: 418 22.
9. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999 354: 20 5.
10. Song SH, Lee JK, Oh MJ et al. Risk factors for the progression or persistence of untreated mild dysplasia of the uterine cervix. Int J Gynecol Cancer 2006 16: 1608 13.
11. Ho GY, Burk RD, Klein S et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995 87: 1365 71.
12. Dalstein V, Riethemuller D, Pretet JL et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003 106: 396 403.
13. Baak JP, Kruse AJ, Robboy SJ, Janssen EA, van Diermen B, Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006 59: 1017 28.
14. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16 (INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003 16: 665 73.
15. Hu L, Guo M, He Z, Thornton J, McDaniel LS, Hughson MD. Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 2005 18: 267 73.
16. Kruse AJ, Baak JP, de Bruin PC, van de Goot FR, Kurten N. Relationship between the presence of oncogenic HPV DNA assessed by polymerase chain reaction and Ki-67 immunoquantitative features in cervical intraepithelial neoplasia. J Pathol 2001 195: 557 62.
17. Bar JK, Harlozinska A, Sediaczek P, Kasiak J, Markowska J. Relations between the expression of p53, c-erB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias. Anticancer Res 2001 21: 1001 6.
18. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002 287: 2114 9.
19. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002 38: 2229 42.
20. Branca M, Ciotti M, Santini D et al. p16 (INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004 23: 354 65.
21. Bose S, Evans H, Lantzy L, Scharre K, Youssef E. p16 (INK4A) is a surrogate biomarker for a subset of human papilloma virus-associated dysplasias of the uterine cervix as determined on the Pap smear. Diagn Cytopathol 2005 32: 21 4.
22. Benevolo M, Mottolese M, Marandino F et al. Immunohistochemical expression of p16 (INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006 19: 384 91.
23. Ishikawa M, Fujii T, Saito M et al. Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 2006 16: 347 53.
24. Nieh S, Chen SF, Chu TY et al. Is p16 (INK 4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. Gynecol Oncol 2005 97: 35 40.
25. Lin ZH, Shen XH, Jin Z et al. Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women. Pathol Int 2005 55: 491 6.
26. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002 2: 342 50.
27. Rosty C, Sheffer M, Tsafrir D et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005 24: 7094 104.
28. Queiroz C, Silva TC, Alves VA et al. P16 (INK4a) expression as a potential prognostic marker in cervical preneoplastic and neoplastic lesions. Pathol Res Pract 2006 202: 77 83.
29. Klaes R, Friedrich T, Spitkovsky D et al. Overexpression of p16 (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001 92: 276 84.
30. Dellas A, Schultheiss E, Almendral AC, Torhorst J, Gudat F. Assessment of EGFR and TGF-alpha expression in relationship to HPV status and Ki-67 distribution in cervical intraepithelial neoplasms. Int J Cancer 1996 69: 165 9.
31. al-Saleh W, Delven P, Greimers R, Fridman V, Doyen J, Boniver J. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesons of the uterine cervix. Correlation with the histologic grade and human papillomavirus type. Am J Clin Pathol 1995 104: 154 60.
32. Kruse AJ, Baak JP, de Bruin PC et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 2001 193: 48 54.
33. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001 8: 83 92.
34. Kruse AJ, Baak JP, Janssen EA et al. Ki-67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 2004 26: 13 20.
35. Kruse AJ, Gudlaugsson E, Helliesen T et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal Quant Cytol Histol 2004 26: 134 40.
36. Alameda F, Fuste P, Boluda S et al. The Ki-67 labeling index is not a useful predictor for the follow-up of cervical intraepithelial neoplasia 1. J Low Genit Tract Dis 2004 8: 313 6.
37. Cricca M, Venturoli S, Morselli-Labate AM et al. HPV DNA patterns and disease implications in the follow-up of patients treated for HPV 16 high-grade carcinoma in situ. J Med Virol 2006 78: 494 500.
38. Costa S, De Nuzzo M, Infante FE et al. Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization. Gynecol Oncol 2002 85: 119 24.
39. Schermerhorn TJ, Hodge J, Saltzman AK, Hackett TE, Sprance HE, Harrison TA. Clinicopathologic variables predictive of residual dysplasia after cervical conization. J Reprod Med 1997 42: 189 92.
40. Livasy CA, Maygarden SJ, Rajaratnam CT, Novotny DB. Predictors of recurrent dysplasia after a cervical loop electrocautery excision procedure for CIN 3: a study of margin, endocervical gland, and quadrant involvement. Mod Pathol 1999 12: 233 8.
41. Reich O, Lahousen M, Pickel H, Tamussino K, Winter R. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet Gynecol 2002 99: 193 6.
42. Reich O, Lahousen M, Pickel H, Winter R. Morphologic changes at the uterine cervix after cold-knife conization. Geburtshilfe Frauenheilkd 2000 60: 273 5.